Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Cyrus R Kumana"'
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
This account describes how orally administered Arsenic-trioxide (ATO) therapy influences the epidemiology of acute promyelocytic leukaemia (APL), and how the experience that ensued may expand the indications for oral ATO as a treatment for diseases/d
Externí odkaz:
https://doaj.org/article/9769a9837e6e4288ad31cc5056855650
Publikováno v:
Pharmaceutics, Vol 14, Iss 9, p 1945 (2022)
Appreciation of the properties of arsenic trioxide (ATO) has redefined the treatment landscape for acute promyelocytic leukaemia (APL) and offers promise as a treatment for numerous other diseases. The benefits of ATO in patients with APL is related
Externí odkaz:
https://doaj.org/article/5354eb50247041d4b174a682e36ed2e3
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Various forms of arsenic were used in China and elsewhere for over 5,000 years. Following the initial success of intravenous arsenic trioxide (i.v. As2O3), we revived an oral formulation of pure As2O3 in 1998 for the treatment of acute promyelocytic
Externí odkaz:
https://doaj.org/article/02226a70d33c42af9d8bf5a9360c6292
Autor:
Harinder Gill, Radha Ragupathy, Carmen Y.Y. Lee, Yammy Yung, Hiu-Tung Chu, Michael Ni, Xiao Xiao, Francis P Flores, Rita Yim, Paul Lee, Lynn Chin, Vivian W.K. Li, Lester Au, Wing-Yan Au, Edmond S.K. Ma, Diwakar Mohan, Cyrus R Kumana, Yok-Lam Kwong
BackgroundThe epidemiology and treatment of acute promyelocytic leukaemia (APL) are changing. We have incorporated oral arsenic trioxide (oral-ATO) into induction/maintenance.MethodsNewly-diagnosed APL from 1991 to 2021 divided into three 10-year per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02e0a4a7ed250df58f0692ee93e8a071
https://doi.org/10.21203/rs.3.rs-1610362/v1
https://doi.org/10.21203/rs.3.rs-1610362/v1
Publikováno v:
Cancer. 126:3244-3254
BACKGROUND The role of arsenic trioxide (As2 O3 ) in the maintenance of first complete remission (CR1) in acute promyelocytic leukemia (APL) is unclear. METHODS A total of 129 consecutive adult patients with APL of all risk categories who achieved CR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afb14bdeec06562bdf92e6f358995110
https://doi.org/10.1002/cncr.32937
https://doi.org/10.1002/cncr.32937
Autor:
CYRUS R KUMANA, BERNARD M Y CHEUNG
Publikováno v:
Journal of the Hong Kong College of Cardiology. 8:41-42
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8442c16cfc0e648e4f766fa9c4df82fb
https://doi.org/10.55503/2790-6744.1463
https://doi.org/10.55503/2790-6744.1463
Autor:
Edmond S. K. Ma, Cyrus R. Kumana, Daniel Cheuk, Yok-Lam Kwong, Harinder Gill, Pui-Kwan Yip, Shau-Yin Ha, Hiu-Tung Chu, Rita Yim, Paul P. Lee, Emily Lee, Wing-Yan Au, Rock Y. Y. Leung, Yammy Yung
Publikováno v:
Blood Adv
Despite therapeutic advances, early death (ED) remains a major factor curtailing survival of acute promyelocytic leukemia (APL). Studies examining factors that cause early death (ED; within 30 days of admission) and the correlation of survival with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95da2b5df84889fe9dfd6e4daf2873d6
https://pubmed.ncbi.nlm.nih.gov/34269798
https://pubmed.ncbi.nlm.nih.gov/34269798
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
Various forms of arsenic were used in China and elsewhere for over 5,000 years. Following the initial success of intravenous arsenic trioxide (i.v. As2O3), we revived an oral formulation of pure As2O3 in 1998 for the treatment of acute promyelocytic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5670f141afd7a6094c8feedfe734aaa
https://doi.org/10.3389/fonc.2020.01294
https://doi.org/10.3389/fonc.2020.01294
Autor:
June S. M. Lau, Bonnie Kho, Yu-Yan Hwang, Ho-Wan Ip, Eric Tse, Vivien Mak, Harinder Gill, Yok-Lam Kwong, Sze-Fai Yip, Rita Yim, Wah Li, Cyrus R. Kumana, Thomas S. Y. Chan, S Y Lin, Wing-Yan Au, Harold K. K. Lee
Publikováno v:
Cancer. 124:2316-2326
Background For patients who have acute promyelocytic leukemia (APL) in second complete remission (CR2), optimal postremission strategies remain undefined. Methods The role of an oral arsenic trioxide (As2 O3 )-based regimen in the management of patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::123d44c8da004c386d4c8caea11cb4be
https://doi.org/10.1002/cncr.31327
https://doi.org/10.1002/cncr.31327
Publikováno v:
Proceedings for Annual Meeting of The Japanese Pharmacological Society. :PO2-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::372bb9c57c55a3a0f8273d5685daccc4
https://doi.org/10.1254/jpssuppl.wcp2018.0_po2-7-2
https://doi.org/10.1254/jpssuppl.wcp2018.0_po2-7-2